Skip to main content

Syneos Health, Inc. (SYNH)

NASDAQ: SYNH · IEX Real-Time Price · USD
98.80 -1.64 (-1.63%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap10.18B
Revenue (ttm)4.98B
Net Income (ttm)250.76M
Shares Out102.99M
EPS (ttm)2.38
PE Ratio41.50
Forward PE20.70
Dividendn/a
Ex-Dividend Daten/a
Volume620,708
Open102.01
Previous Close100.44
Day's Range97.91 - 102.18
52-Week Range60.38 - 104.18
Beta1.78
AnalystsBuy
Price Target113.38 (+14.8%)
Earnings DateNov 3, 2021

About SYNH

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist c...

IndustryLife Sciences Tools & Services
IPO DateNov 7, 2014
Employees24,310
Stock ExchangeNASDAQ
Ticker SymbolSYNH
Full Company Profile

Financial Performance

In 2020, Syneos Health's revenue was $4.42 billion, a decrease of -5.56% compared to the previous year's $4.68 billion. Earnings were $192.79 million, an increase of 46.88%.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for Syneos Health stock is "Buy." The 12-month stock price forecast is 113.38, which is an increase of 14.76% from the latest price.

Price Target
$113.38
(14.76% upside)
Analyst Consensus: Buy

News

Here's Why You Should Hold on to Syneos Health (SYNH) for Now

Investors about optimistic about Syneos Health (SYNH) given its better-than-expected results as well as strong segmental performance during the third quarter.

3 days ago - Zacks Investment Research

Why Syneos Health (SYNH) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

1 week ago - Zacks Investment Research

Labcorp In Talks To Merge Some Covance Assets With Syneos: Bloomberg

Laboratory Corp of America Holdings (NYSE: LH) is in talks to combine some of its assets with Syneos Health Inc (NASDAQ: SYNH), reports Bloomberg citing people with knowledge of the matter.  The compani...

Other symbols:LH
2 weeks ago - Benzinga

Syneos Health to Present at Upcoming Investor Conferences

MORRISVILLE, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that the Company is scheduled to pr...

2 weeks ago - GlobeNewsWire

Syneos Health (SYNH) Q3 Earnings Top Estimates, 2021 EPS View Up

Syneos Health (SYNH) reports better-than-expected results for third-quarter 2021 on strength in Clinical Solutions and Commercial Solutions arms driving the top line.

3 weeks ago - Zacks Investment Research

Syneos Health (SYNH) Q3 Earnings and Revenues Surpass Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 3.39% and 0.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Syneos Health Reports Third Quarter 2021 Results

Highlights

3 weeks ago - GlobeNewsWire

Syneos Health (SYNH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago - Zacks Investment Research

Syneos Health Schedules Third Quarter 2021 Earnings Call for Wednesday, November 3rd, 2021

MORRISVILLE, N.C., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2021 financial resul...

1 month ago - GlobeNewsWire

Syneos Health's (SYNH) New Pact Boosts Tech-Driven Solutions

Syneos Health's (SYNH) recent acquisition boosts the company's ability to deliver strategic insights and technology-enabled solutions that address the customers' most complex data challenges.

1 month ago - Zacks Investment Research

Syneos Health Acquires RxDataScience

Acquisition Delivers AI and Data Engineering Expertise, Enterprise Analytics and Technology-Enabled Solutions to Accelerate Customer Performance Acquisition Delivers AI and Data Engineering Expertise, E...

1 month ago - GlobeNewsWire

Here's Why You Should Retain Syneos Health (SYNH) For Now

Investors are optimistic about Syneos Health (SYNH), given the strength in its Clinical Solutions business and notable partnership deals.

1 month ago - Zacks Investment Research

Syneos Health's (SYNH) New Buyout Boosts Clinical Solutions Arm

Syneos Health (SYNH) acquisition of StudyKIK strengthens the former's ability to provide technology and insight-driven solutions.

2 months ago - Zacks Investment Research

Syneos Health Acquires StudyKIK

Acquisition Offers Sites and Sponsors Access to Technology-Enabled, Insight-Powered Solutions, Accelerating Clinical Trial Recruitment, Retention and Diversity Acquisition Offers Sites and Sponsors Acce...

2 months ago - GlobeNewsWire

Syneos Health (SYNH) Enhances Clinical Trials With New Pact

Syneos Health (SYNH) recent partnership develops a more patient-centric travel experience, advances diversity and inclusion in clinical research.

2 months ago - Zacks Investment Research

Syneos Health and Ride Health Partner to Improve Clinical Trial Recruitment and Retention

Partnership Creates a More Patient-centric Travel Experience, Drives Adherence and Advances Diversity and Inclusion in Clinical Research Partnership Creates a More Patient-centric Travel Experience, Dri...

2 months ago - GlobeNewsWire

Syneos Health (SYNH) Up 11.8% Since Last Earnings Report: Can It Continue?

Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

Syneos Health (SYNH) Hits a 52-Week High: What's Driving It?

Strong performance by the Clinical Solutions and Commercial Solutions segments drove Syneos Health's (SYNH) top line.

2 months ago - Zacks Investment Research

Syneos Health to Present at the 2021 Baird Global Healthcare Conference

MORRISVILLE, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Alista...

2 months ago - GlobeNewsWire

Syneos Health (SYNH) Q2 Earnings Top Estimates, 2021 View Up

Syneos Health (SYNH) reported better-than-expected revenues for the second quarter of 2021 on strong segmental performance.

3 months ago - Zacks Investment Research

Syneos Health (SYNH) Surpasses Q2 Earnings and Revenue Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 3.19% and 0.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Syneos Health: Q2 Earnings Insights

Shares of Syneos Health (NASDAQ:SYNH) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 67.24% year over year to $0.97, which beat the estimate of $0.96.

3 months ago - Benzinga

Syneos Health Reports Second Quarter 2021 Results

Highlights

3 months ago - GlobeNewsWire

Syneos Health (SYNH) Earnings Expected to Grow: Should You Buy?

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Syneos Health and Aetion Partner to Offer RWE Solutions to Advance Drug Development and Commercialization

Partnership will enable biopharma companies to accelerate clinical development, market access, and the uptake of new therapies Partnership will enable biopharma companies to accelerate clinical developm...

3 months ago - GlobeNewsWire